Implication of foam sclerosant inactivation by human whole blood in a laboratory setting

Abstract

Background

During sclerotherapy, it has been recommended to confirm intravenous placement of the needle by aspirating blood into the sclerosant syringe. This may inactivate some, or all of the sclerosant.

Aims

To quantify the volume of human blood needed to completely inactivate 1 ml of sodium tetradecyl sulphate, and comparing fresh blood and blood that has been stored in an ethylenediaminetetraacetic acid tube.

Methods

A series of manual titrations were carried out following a procedure developed at STD Pharmaceutical Products Ltd (Hereford, UK) and listed in the British Pharmacopeia. Three percent of sodium tetradecyl sulphate stock solutions were made with increasing volumes of blood and titrated against benzethonium chloride to determine the active concentration (% w/v) of sodium tetradecyl sulphate remaining in the solution.

Results

A calculated approximation showed 0.3 ml of blood is required to fully inactivate 1 ml of 3% sodium tetradecyl sulphate when made into a foam. A comparison was made between the use of fresh blood and blood stored in ethylenediaminetetraacetic acid tubes. Blood stored in ethylenediaminetetraacetic acid tubes showed more inactivation of sodium tetradecyl sulphate, but this was not significant at the P ≤ 0.05 level.

Conclusion

The data from our study have shown that a minimum of 0.3 ml of fresh blood is required to inactivate 1 ml of 3% sodium tetradecyl sulphate as a foam and it is not significantly affected by storing blood in an ethylenediaminetetraacetic acid tube. Our methodology suggests that during foam sclerotherapy treatment, blood should not be aspirated into the syringe to confirm position, and that ultrasound guidance is more appropriate for needle placement.

Keywords

Sclerotherapy sclerosant sodium tetradecyl sulphate

Get full access to this article

View all access options for this article.

References

Reiner

. The activity of anionic surface active compounds in producing vascular obliteration. Exp Biol Med 1946; 62: 49–54.

National Institute for Health and Care Excellence. Varicose veins in the legs: the diagnosis and management of varicose veins. NICE Clinical Guideline 168, http://nice.org.uk/guidance/CG168 (accessed 20 May 2015).

Parsi

. Interaction of detergent sclerosants with cell membranes. Phlebology 2015; 30: 306–315.

Cooley-Andrade

Goh

Connor

et al.

Detergent sclerosants simulate leukocyte apoptosis and oncosis. Eur J Vasc Endovasc Surg 2016; 51: 846–856.

Whiteley

Dos Santos

Fernandez-Hart

et al.

Media damage following detergent sclerotherapy appears to be secondary to the induction of inflammation and apoptosis: an immunehistochemical study elucidating previous histological observations. Eur J Vasc Endovasc Surg 2016; 51: 421–428.

Myers

Jolley

Clough

et al.

Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 33: 116–121.

Gonzalez-Zeh

Armisen

Barahona

. Endovenous laser and echo-guided foam ablation in great saphenous vein reflux: one-year follow-up results. J Vasc Surg 2008; 48: 940–946.

Parsi

Exner

Connor

et al.

The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro. Eur J Vasc Endovasc Surg 2008; 36: 216–223.

Tessari

Izzo

Cavezzi

et al.

Timing and modality of the sclerosing agents binding to the human proteins: laboratory analysis and clinical evidences. Veins Lymphat 2014; 3: 36–40.

10.

Parsi

Exner

Low

et al.

In vitro effects of detergent sclerosants on antithrombotic mechanisms. Eur J Vasc Endovasc Surg 2009; 38: 220–228.

11.

Tessari

Cavezzi

Frullini

. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001; 27: 58–60.

12.

Rabe

Breu

Cavezzi

et al.

European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014; 29: 338–354.

13.

Watkins

. Deactivation of sodium tetradecyl sulphate injection by blood proteins. Eur J Vasc Endovasc Surg 2011; 41: 521–525.

14.

British Pharmacopoeia. Clifton House, Worship Street, London. EC2A 2EJ: By British Pharmacopoeia Commission. The Stationary Office Ltd, 2009.

15.

Patela

Ostler

Dos Santos

et al.

The effects of environmental and compositional manipulations on the longevity of Tessari-made foam for sclerotherapy. J Vasc Surg Venous Lymphat Disord 2015; 3: 312–318.

16.

Parsi

. Interaction of detergent sclerosants with cell membranes. Phlebology 2014; 30: 306–315.

17.

Parsi

Exner

Connor

et al.

In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34: 731–740.

18.

Jones

. A theoretical approach to the binding of amphipathic molecules to globular proteins. Biochem J 1975; 151: 109–114.

19.

Connor

Cooley-Andrade

Goh

et al.

Detergent sclerosants are deactivated and consumed by circulating blood cells. Eur J Vasc Endovasc Surg 2015; 49: 426–431.

20.

Crosley

Duthie

Polley

et al.

Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics. Genes Nutr 2009; 4: 95–102.